Bicara Therapeutics (BCAX) Current Assets (2023 - 2026)

Bicara Therapeutics' Current Assets history runs 4 years deep, the most recent figure standing at $544.9 million for Q1 2026.

• On a quarterly basis, Current Assets rose 15.75% year-over-year to $544.9 million in Q1 2026; TTM through Mar 2026 was $544.9 million, a 15.75% increase from a year earlier, with the FY2025 full-year figure at $422.1 million, down 16.01% from the prior year.
• Current Assets grew to $544.9 million in Q1 2026 per BCAX's latest filing, from $422.1 million in the prior quarter.
• Across five years, Current Assets topped out at $544.9 million in Q1 2026 and bottomed at $231.1 million in Q4 2023.
• The 4-year median for Current Assets is $457.6 million (2025), against an average of $429.3 million.
• Across the five-year window, Current Assets surged 117.48% in 2024 and slumped 42.98% in 2025, its largest moves.
• Year by year, Current Assets stood at $231.1 million in 2023, then jumped by 117.48% to $502.5 million in 2024, then decreased by 16.01% to $422.1 million in 2025, then climbed by 29.11% to $544.9 million in 2026.
• Per Business Quant, the three latest BCAX Current Assets figures stand at $544.9 million (Q1 2026), $422.1 million (Q4 2025), and $297.4 million (Q3 2025).